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Abstract
Background: For breast cancer patients diagnosed with estrogen receptor (ER)-positive tumors, treatment with
tamoxifen is the gold standard. A significant number of patients, however, develop resistance to tamoxifen, and
management of such tamoxifen-resistant patients is a major clinical challenge. With an eye to identify novel targets
for the treatment of tamoxifen-resistant tumors, we observed that tamoxifen-resistant cells derived from ER-positive
MCF-7 cells (MCF7TR) exhibit an increased expression of microRNA-10b (miR-10b). A role of miR-10b in drug-
resistance of breast cancer cells has never been investigated, although its is very well known to influence invasion
and metastasis.
Methods: To dileneate a role of miR-10b in tamoxifen-resistance, we over-expressed miR-10b in MCF-7 cells and
down-regulated its levels in MCF7TR cells. The mechanistic role of HDAC4 in miR-10b-mediated tamoxifen
resistance was studied using HDAC4 cDNA and HDAC4-specific siRNA in appropriate models.
Results: Over-expression of miR-10b in ER-positive MCF-7 and T47D cells led to increased resistance to tamoxifen
and an attenuation of tamoxifen-mediated inhibition of migration, whereas down-regulation of miR-10b in MCF7TR
cells resulted in increased sensitivity to tamoxifen. Luciferase assays identified HDAC4 as a direct target of miR-10b.
In MCF7TR cells, we observed down-regulation of HDAC4 by miR-10b. HDAC4-specific siRNA-mediated inactivation
of HDAC4 in MCF-7 cells led to acquisition of tamoxifen resistance, and, moreover, reduction of HDAC4 in MCF7TR
cells by HDAC4-specific siRNA transfection resulted in further enhancement of tamoxifen-resistance.
Conclusions: We propose miR-10b-HDAC4 nexus as one of the molecular mechanism of tamoxifen resistance
which can potentially be expolited as a novel targeted therapeutic approach for the clinical management of
tamoxifen-resistant breast cancers.
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Background
The problem of drug-resistance is a major clinical con-
cern for the successful management of cancer patients.
Estrogen receptor (ER) is expressed in 75 % of breast
cancers [1] and for such breast cancers, tamoxifen is one
of the important drug of choice for targeted personalized
therapy. Tamoxifen can significantly lower the chances
of developing recurrent breast cancer and can be very
effective in women who initially present with metastatic
disease. It remains the primary therapeutic agent for the
management of ER and/or progesterone receptor (PR)-ex-
pressing breast cancers, particularly in premenopausal
women without or with conventional chemotherapeutics.
However, many ER-positive cancers that initially respond
to tamoxifen, eventually develop resistance with the con-
tinued administration of the drug [2]. Acquired resistance
to tamoxifen is seen in 30–40 % of breast cancer patients
treated with tamoxifen for 5 years [3], which clearly
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indicates that this is a major clinical problem. The tumors
that have acquired drug resistance are usually far more
aggressive and difficult to treat with conventional ther-
apeutics. They are invariably linked to poor prognosis
as well as overall poor survival.
There is an emerging interest in microRNAs (miRNAs)
as therapeutic targets in drug-resistant cancers [4]. These
short non-coding RNAs have been implicated in multiple
stages of cancer progression and metastasis, and reports
in the last few years have indicated the involvement of
miRNAs in tamoxifen resistance as well [5–11]. The miR-
NAs directly or indirectly implicated in tamoxifen resist-
ance in breast cancer models include miR-221/222 [5, 6],
miR-15a/16 [7], miR-342 [8], miR-375 [9], miR-200 s [10],
miR-126/miR-10a [11] and miR-519a [12]. We designed
the current study to investigate miRNA-regulation of tam-
oxifen resistance, and used paired cell lines – parental
MCF-7 and tamoxifen resistant MCF-7 (MCF7TR) as our
model. Tamoxifen resistance has been linked to epithelial-
mesenchymal transition (EMT) through an involvement
of miR-375 [9], and EMT-regulating miRNAs such as
miR-200 s [13, 14] and let7s [15] have been reported to
play a role in resistance to tamoxifen [10]. In our model,
we observed increased invasion of MCF7TR cells, a
phenomenon which has been linked to EMT [16], which
prompted us to investigate the miRNAs that have been
linked to invasion and EMT characteristics of breast can-
cer cells. We observed a significant over-expression of
miR-10b in MCF7TR cells which correlated with ac-
quired tamoxifen resistance. Mechanistically, we identi-
fied HDAC4 as a target of miR-10b which mediated the
miR-10b action. Our results provide the first evidence
in support of such action of miR-10b and HDAC4 and
further highlight the importance of miRNA-regulation
in drug resistance phenotype.
Methods
Cell lines and reagents
MCF-7 and T47D breast cancer cells were purchased
from ATCC and maintained in DMEM and RPMI med-
iam (Invitrogen, Carlsbad, CA), respectively, with 10 %
fetal bovine serum, 100 units/ml penicillin, and 100 μg/
ml streptomycin in a 5 % CO2 atmosphere at 37 °C. The
tamoxifen resistant MCF-7 derivatives, MCFTR cells,
were generated by culturing parental MCF-7 cells in
DMEM medium supplemented with 5 % FBS, antibi-
otics and 10−6 M 4-hydroxy tamoxifen. Concentration
of tamoxifen was gradually increased until the final
concentration was 10−6 M. Cells were continuously ex-
posed to tamoxifen for 6 months during which time the
medium was replaced every 3 to 4 days. The cell lines
have been tested and authenticated in the core facility
(Applied Genomics Technology Center at Wayne State
University) by short tandem repeat profiling using the
PowerPlex 16 System from Promega. Antibodies were
purchased from following sources – HDAC4 (Cell Sig-
naling) and β-actin (Sigma-Aldrich).
Western blot analysis
For Western blot analysis, cells were lysed in RIPA buf-
fer containing complete mini EDTA-free protease inhibi-
tor cocktail (Roche) and phosphatase inhibitor cocktails
1 and 2 (Sigma-Aldrich). After resolution on 12 % poly-
acrylamide gels under denaturing conditions, proteins
were transferred to nitrocellulose membranes, incu-
bated with appropriate primary/horseradish peroxidase-
conjugated secondary antibodies and visualized using
chemiluminescence detection system (Pierce).
Cell growth inhibition studies by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay
Cells were seeded at a density of 5 x 103 cells per well in
96-well culture plates. After overnight incubation, liquid
medium was removed and replaced with a fresh medium
containing DMSO (vehicle control) or different concen-
trations of tamoxifen, as indicated. After 48 h, 25 μl of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) solution (5 mg/ml in phosphate-buffered saline,
PBS) was added to each well and incubated further for 2 h
at 37 °C. Upon termination, the supernatant was aspirated
and the MTT formazan, formed by metabolically viable
cells, was dissolved in DMSO (100 μl) by mixing for
30 min on a gyratory shaker. The absorbance was mea-
sured at 595 nm on Ultra Multifunctional Microplate
Reader (TECAN, Durham, NC).
Cell viability studies by Trypan Blue assay
Cells were seeded in 6-well culture plates and appropri-
ately treated. Upon completion of incubation, culture
medium (with floating dead cells) was collected and
pooled with the adherent cells removed from the plate
by trypsinization. The cells were briefly spun and re-
suspended in the normal culture medium. Cell viability
was assessed by adding 50 μl of Trypan Blue solution
(0.4 % in PBS) to 50 μl of the cell suspension. After
2 min, the number of living cells, which did not retain
the dye was counted using a hemocytometer, and was
compared to the total number of cells (living + dead) to
calculate the viability percentage.
Histone/DNA ELISA for detection of apoptosis
The Cell Death Detection ELISA Kit (Roche) was used
to detect apoptosis. Cells were treated, as indicated for
individual experiments. After treatment, the cytoplasmic
histone/DNA fragments from these cells were extracted
and incubated in the microtiter plate modules coated
with anti-histone antibody. Subsequently, the peroxidase-
conjugated anti-DNA antibody was used for the detection
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of immobilized histone/DNA fragments followed by color
development with ABTS substrate for peroxidase. The
spectrophotometric absorbance of the samples was deter-
mined by using Ultra Multifunctional Microplate Reader
(TECAN) at 405 nm.
miRNA transfections
Transfections of pre/anti-miR-10b were done using
methodology previously described [13]. Briefly, cells
were seeded (2.5 × 105 cells per well) in six well plates
and transfected with pre/anti-miR-10b or non-specific
pre/anti-miRNA controls (Life Technologies) at a final
concentration of 200 nM, using DharmaFECT transfec-
tion reagent (Dharmacon). After 48 h of transfection,
cells were passaged and transfected once again before
being used in the experiment.
Real-time RT-PCR
Real-Time RT-PCR analyses were done as described
previously [13]. Total RNA was isolated using the
mirVana miRNA isolation kit (Life Technologies). The
levels of miRNAs were determined using miRNA-
specific Taqman probes from the Taqman MicroRNA
Assay (Life Technologies). The relative amounts of
miRNA were normalized to RNU48.
Cell migration and invasion assays
Cell migration and invasion assays were performed using
24 well transwell permeable supports with 8 μM pores
(Corning) [13]. After transfections with pre/anti-miR-
10b or the non-specific controls, as described above,
cells were suspended in serum free medium and seeded
into the transwell inserts. For invasion assays, the trans-
well inserts were coated with growth factor reduced
Matrigel (BD Biosciences). Bottom wells were filled with
complete media. After 24 h, cells were stained with
4 μg/ml calcein AM (Life Technologies) in PBS at 37 °C
for 1 h. Cells were detached from inserts by trypsiniza-
tion and fluorescence of the invaded cells was read in
ULTRA Multifunctional Microplate Reader (TECAN,
San Jose, CA).
Luciferase assay
For luciferase reporter assays, MCF-7 cells were co-
transfected with HDAC4 3′UTR luciferase vector
(GeneCopoeia, Catalog # HmiT023167-MT05) and pre-
miR-10b or miRNA negative control, using DharmaFECT
Duo Transfection Reagent (Dharmacon). The vector has
HDAC4 3′ UTR sequence inserted downstream of the se-
creted Gaussia luciferase (GLuc) reporter gene system,
driven by SV40 promoter for expression in mammalian
cells. A secreted Alkaline Phosphatase (SEAP) reporter,
driven by a CMV promoter, is also cloned into the same
vector (pEZX-MT05) and serves as the internal control.
48 h post- transfection, Gluc and SEAP luciferase activities
were assayed using Secrete-Pair™Dual Luminescence Assay
Kit (GeneCopoeia), following exactly the same procedure
as described in the vendor’s protocol.
Results
Tamoxifen resistant MCF7 showed elevated expression of
miR-10b
Tamoxifen resistance has been linked with epithelial-to-
mesenchymal transition (EMT) [9, 16], which in turn is
linked to breast cancer invasion [16]. Therefore, we
started our investigations with an evaluation of the rela-
tive invasive potential of MCF7TR cells, and we found
that MCF7TR cells are highly invasive (p < 0.01), com-
pared to their parental cells (Fig. 1a). Next we screened
several miRNAs that have been linked with EMT and in-
vasion of breast cancer cells, namely let-7 s, miR-200 s
and miR-10b. No significant difference in the expression
of let-7 and miR-200 family miRNAs was observed in
MCF7TR cells, relative to MCF-7 cells; however, a very
significant up-regulation (more than 7-folds, p < 0.01) of
miR-10b expression was seen (Fig. 1b).
miR-10b expression correlated with tamoxifen sensitivity
To investigate whether elevated miR-10b levels in
MCF7TR cells may have a role in determining resistance
to tamoxifen, we over-expressed miR-10b in parental
MCF-7 cells and exposed the cells to increasing concen-
trations of tamoxifen. We observed a dose-dependent
inhibition of cell growth in control MCF-7 cells with IC-
50 less than 5 μM, and more than 90 % inhibition at
20 μM tamoxifen concentration (Fig. 2a). However, a
significant resistance to tamoxifen was seen in MCF-7
cells that were transfected with pre-miR-10b, with IC-50
increased ~7-8-folds (Fig. 2a). In order to rule out cell
line-specific effects, we confirmed our findings in an-
other ER-positive breast cancer cell line, T47D. Similar
to MCF-7 cells, tamoxifen inhibited cell proliferation in
T47D cells but transfections with pre-miR-10b resulted
in a significant inhibition of tamoxifen action in the
T47D cells as well (Fig. 2a), which is similar to the data
obtained from the MCF7 cells. Further, we confirmed
our results in a reciprocal experimental setup where we
down-regulated miR-10b in MCF7TR cells. As shown in
Fig. 2b, we found that control MCF7TR cells are quite
resistant to tamoxifen but antagonizing miR-10b expres-
sion, by the use of specific anti-miR-10b oligonucleo-
tides, resulted in sensitization of these cells to tamoxifen
with IC50 close to 5 μM. Next, we evaluated the effect of
tamoxifen on migration potential of MCF-7 and T47D
cells and observed a marked reduction in migration of
both of these cell lines when treated at a dose of 5 μM for
48 h (Fig. 2c). However, prior transfections with miR-10b
significantly (p < 0.001 for MCF-7 and p < 0.05 for T47D
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cells) attenuated the tamoxifen-mediated inhibition of mi-
gration (Fig. 2c). Since we observed similar results in both
MCF-7 and T47D cells, we performed further mechanistic
studies in MCF-7 cells.
It is known that tamoxifen induces apoptosis in MCF-7
cells [7, 8], therefore, we looked at the tamoxifen-induced
apoptosis in our model system to further correlate miR-
10b levels with tamoxifen action. Tamoxifen treatment re-
sulted in the induction of apoptosis in a dose-dependent
manner in MCF-7 cells which was attenuated by transfec-
tion with pre-miR-10b (Fig. 3a). In MCF7TR cells, while
non-specific anti-miRNA transfected cells did not exhibit
much induction of apoptosis, transfection of anti-miR-10b
resulted in a dose-dependent induction of apoptosis
(Fig. 3b), again suggestive of sensitization of these cells to
tamoxifen through deregulation of miR-10b. We also
looked at the effect of miR-10b expression on invasive po-
tential. Pre-miR-10b transfected MCF-7 cells were signifi-
cantly much more invasive (Fig. 3c) while anti-miR-10b
transfected MCF7TR cells were significantly less invasive,
compared to respective controls (Fig. 3d). Collectively,
these results provided a clear functional involvement of
miR-10b in tamoxifen resistance.
HDAC4 is a novel target of miR-10b
Having established a role of miR-10b in tamoxifen resist-
ance, we next studied the molecular mechanism of such
action of miR-10b by looking at its potential targets. We
started with an Ingenuity Pathway Analysis to list the
potential targets of miR-10b. A number of targets such
as CD44, TWIST, HOXA1, HOXD10, HDAC4, PKD1,
KLF4, etc. were found (Fig. 4a). We further scanned Tar-
getScan/microRNA.org as well as reported literature for
the potential targets of miR-10b and tested whether the
potential targets were differentially expressed in MCR-7
vs. MCF7TR cells. Based on such screening, we focused
on HDAC4, and the results presented in Fig. 4b show an
alignment of miR-10b with its predicted site on
HDAC4′s 3′ UTR. Next, we performed luciferase assays
to confirm binding of miR-10b to 3′UTR of HDAC4.
MCF-7 cells were co-transfected with pre-miR-10b (or
control pre-miRNA) and pEZX-MT05 vector that car-
ried the cloned HDAC4 3′UTR sequence. As can be
seen in Fig. 4c, the luciferase activity was inhibited in
cells transfected with pre-miR-10b by almost 50 %, com-
pared to the control cells. These results suggested a dir-
ect binding of miR-10b to 3′UTR of HDAC4. Consistent
Fig. 1 miR-10b in tamoxifen-resistant MCF-7 cells. a Tamoxifen-resistant MCF-7 cells (MCF7TR) showed significantly higher invasive potential, compared
to parental MCF-7 cells. b Screening of miRNAs in MCF7TR cells, relative to the levels in MCF-7 cells, by real time RT-PCR. RNU48 was used as internal
control for the real-time RT-PCR miRNA analysis.
Fig. 2 Effect of miR-10b levels on response to tamoxifen. a Ectopic over-expression of miR-10b in MCF-7 and T47D cells, through transfections with
pre-miR-10b oligonucleotides, increased tamoxifen resistance, (b) silencing of miR-10b in MCF7TR cells, through transfections with anti-miR-10b
oligonucleotides, decreased their tamoxifen resistance and (c) ectopic over-expression of miR-10b in MCF-7 and T47D cells significantly attenuated
tamoxifen-induced inhibition of migration potential. Cells were treated with indicated doses of tamoxifen for 48 h. *p < 0.05, **p < 0.01
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Fig. 3 Effect of miR-10b levels on apoptosis-induction and invasion. Effect of miR-10b levels on apoptosis-induction in (a) MCF-7 and (b) MCF7TR
cells. Induction of apoptosis was assessed by DNA Histone-ELISA assay. Invasion of (c) MCF-7 and (d) MCF7TR cells was assessed by plating cells
in matrigel-coated plates MCF-7, non-specific pre-miRNAs transfected MCF-7 cells; MCF-7 + pre-miR-10b, pre-miR-10b transfected MCF-7 cells;
MCF7TR, non-specific anti-miRNAs transfected MCF7TR cells; MCF7TR + anti-miR-10b, anti-miR-10b transfected MCF7TR cells.
Fig. 4 HDAC4 is a target of miR-10b. a Ingenuity Pathway Analysis for targets of miR-10b. HDAC4 is shown with an arrow. b Sequence
complementarities of miR-10b and its target HDAC4. c Luciferase assay was conducted to confirm that HDAC4 is a direct target of
miR-10b. MCF-7 cells were co-transfected with dual luciferase plasmid pEZX-MT05-HDAC4-3′UTR along with a control pre-miR or pre-miR-
10b, and assayed for luciferase activity 48 h after transfection. d Levels of HDAC4 in parental (MCF-7) and tamoxifen-resistance MCF-7
(MCF7TR) cells. e Effect of altered miR-10b levels on HDAC4 levels. β-actin protein was used as protein loading control for Western blots
and RNU48 was used as internal control for the real-time RT-PCR miRNA analysis. C, control; PM, pre-miR-10b; AM, anti-miR-10b
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with this direct evidence, we further obtained additional
data in support of HDAC4 being a valid target of miR-
10b, and we found significantly down-regulated expres-
sion of HDAC4 in high miR-10b expressing MCF7TR
cells (Fig. 4d). To further establish the regulation of
HDAC4 by miR-10b, we also tested the expression of
HDAC4 in parental MCF-7 cells with or without trans-
fection with pre-miR-10b. Ectopic expression of miR-
10b resulted in the down-regulation of HDAC4 in
MCF-7 cells and, conversely, down-regulation of miR-
10b in MCF7TR cells resulted in increased expression
of HDAC4 (Fig. 4e).
HDAC4 is mechanistically involved in miR-10b-influenced
tamoxifen resistance
Next we asked the question whether miR-10b mediated
regulation of HDAC4 is relevant to miR-10b’s influence
on tamoxifen resistance. We used specific siRNA against
HDAC4 to down-regulate its expression. Fig. 5a demon-
strates an efficient down-regulation of HDAC4 by
siRNA. When exposed to increasing concentrations of
tamoxifen, silencing of HDAC4 mimicked the effects of
transfections with pre-miR-10b (Fig. 5b). Moreover, re-
expression of HDAC4 in pre-miR-10b transfected MCF-7
cells, by the use of HDAC4 cDNA, re-sensitized these
cells to tamoxifen. As a confirmation of our results in the
reciprocal model, antagonizing miR-10b made MCF7TR
cells responsive to tamoxifen, and silencing of HDAC4 in
these very cells made the cells resistant to tamoxifen
(Fig. 5c). Although MCF7TR cells already have low basal
levels of HDAC4 (Fig. 4d), further knock-down of HDAC4
by the use of specific siRNA led to further diminishing the
effects of increasing doses of tamoxifen (Fig. 5c).
HDAC4 regulation by miR-10b determines cellular response
to tamoxifen
We subsequently tested the role of HDAC4 in tamoxifen-
induced apoptosis and found that whereas pre-miR-10b
transfection made MCF-7 cell resistant to tamoxifen-
induced apoptosis, an effect particularly evident at 20 μM
dose (Fig. 6a), re-expression of HDAC4 led to overcome
tamoxifen resistance. A similar effect was seen when
we quantitated live cells after tamoxifen treatment,
and re-expression of HDAC4 clearly negated the ef-
fects of miR-10b transfection (Fig. 6b). In MCF7TR
cells, silencing of HDAC4 was observed to reverse
the effects of anti-miR-10b, both on apoptosis induc-
tion (Fig. 6c) as well as viability of cells (Fig. 6d).
Taken together, these results demonstrated a func-
tional importance of HDAC4 in miR-10b-mediated re-
sponse of ER-positive cells to tamoxifen treatment.
Finally, we questioned whether there is any evidence for
such molecular events in clinical samples. While there is
evidence connecting miR-10b with clinical outcome in
breast cancer patients [17], no such information is avail-
able for HDAC4. To evaluate if the down-regulation of
HDAC4, as observed by us, has any clinical significance,
we turned to public databases and data-mining tools. We
first searched for evidence of under-expression of HDAC4
in breast cancer patients, relative to normal patients, using
the online data mining platform Oncomine. We found a
few studies/data sets supporting down-regulation of
HDAC4 in breast cancer samples, relative to normal
Fig. 5 Effect of HDAC4 levels on tamoxifen-sensitivity. a siRNA against HDAC4 reduced its expression in MCF-7 cells. Functional role of HDAC4 and
miR-10b on tamoxifen sensitivity in b MCF-7 and c MCF7TR cells. β-actin protein was used as protein loading control for Western blots. Tamoxifen
treatment was done for 48 h at indicated doses. PM, pre-miR-10b; AM, anti-miR-10b; HDAC4, HDAC cDNA; siHDAC4, siRNA against HDAC4
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controls (p ≤ 0.05) (Additional file 1: Table S1). We also
evaluated the correlation of HDAC4 expression with re-
lapse free survival of breast cancer patients. For this, we
turned to Kaplan Meier plotter, a publicly available tool
that integrates survival data from GEO, EGA and TCGA
to generate Kaplan Meier plots [18]. As seen in Additional
file 2: Figure S1, breast cancer patients with low expres-
sion of HDAC4 had poor relapse free survival, compared
to those with high expression (p < 0.01). A total of 3554
breast cancer samples were analysed for this comprehen-
sive relapse free survival plot. We also turned to Onco-
mine database to look for clinical data on HDAC4
expression in ER-positive samples and observed lower
expression of HDAC4 in ER-positive samples in, at
least, one study (Additional file 3: Figure S2). Inter-
estingly, there is evidence to suggest a negative cor-
relation between HDAC4 and ER, where HDAC4 was
found to transcriptionally suppress ER expression
[19]. Collectively, the data mining from public data-
bases supports our conclusions, suggesting that lower
HDAC4 levels correlate with advanced breast cancers
with poor prognosis.
Discussion
The major conclusions from our present study are a) en-
dogenous levels of miR-10b are significantly higher in
MCF7TR cells, the tamoxifen-resistant derivatives of
MCF-7 cells; b) induced expression of miR-10b in MCF-
7 cells, by pre-miR-10b oligonucleotides, was correlated
with increased invasion and resistance to tamoxifen-
induced apoptosis while reduced expression of miR-10b
in MCF7TR cells, by anti-miR-10b oligonucleotides,
inhibited invasion along with reduced resistance to tam-
oxifen; c) HDAC4 appears to be an important target of
miR-10b; its expression was found to correlate inversely
with miR-10b levels and its levels modulated by altered
miR-10b levels; and d) functional significance of HDAC4
regulation by miR-10b was suggested by the observation
that over-expression of HDAC4 reversed tamoxifen re-
sistance induced by ectopic expression of miR-10b in
Fig. 6 miR-10b and its target HDAC4 influence tamoxifen-induced apoptosis and cell viability. Effect of ectopic expression of miR-10b and HDAC4 on
(a) apoptosis-induction and (b) viability of MCF-7 cells, and the effect of silencing of miR-10b and HDAC4 on (c) apoptosis-induction and (d) viability of
MCF7TR cells. Tamoxifen treatment was for 48 h. PM, pre-miR-10b; AM, anti-miR-10b; HDAC4, HDAC cDNA; siHDAC4, siRNA against HDAC4
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MCF cells, and silencing of HDAC4 attenuated the ef-
fects of anti-miR-10b transfections in MCF7TR cells.
Most targeted therapies are known to work initially but
with the passage of time and continued administration,
patients eventually develop resistance to the therapeutic
agent, and this process is called extrinsic (acquired) drug
resistance. While intrinsic (de novo) drug resistance char-
acterized by resistance to therapy right from the beginning
is itself clinically challenging, the phenomenon of acquired
drug resistance is equally a big concern. Tamoxifen is an
ER-targeting drug which is used for the successful man-
agement of ER-driven breast cancers. Acquired resistance
to tamoxifen [20] is a major clinical concern and a survey
of literature suggests that the major mechanisms currently
under investigation include EMT and the cancer stem
cells (CSCs). Multiple studies have provided direct as well
as indirect evidence supporting this notion. In support of
a mechanistic role of EMT in tamoxifen resistance of
breast cancer cells, over-expression of Pin-1 [21], AKT
[22], Nicastrin and Notch4 [23], FoxM1 [24], brachyury
[25] as well as modulation of several microRNAs [9, 10]
has been reported. Involvement of CSCs in tamoxifen re-
sistance of breast cancer cells has been reported, which
appears to be mechanistically linked with higher expres-
sion of CXCR4 [26], STAT3 [27], Sox2 [28], EZH2 [29],
and lower expression of CD24 [30, 31].
Here we report a novel role of miR-10b in tamoxifen
resistance of breast cancer cells. Tamoxifen-resistant
breast cancer cells exhibit increased invasive potential, a
phenomenon that is well established for high miR-10b
expressing breast cancer cells [17, 32]. A recent report
[33] has identified critical role of miR-10b in TGF-β1-
induced EMT. In this work, miR-10b was found to be a
downstream target of TGF-β1, essential for TGF-β1-
induced down-regulation of epithelial marker E-cadherin
and up-regulation of mesenchymal marker vimentin. Inhib-
ition of miR-10b in metastatic breast cancer MDA-MB-231
and MDA-MB-435 cells significantly reversed the TGF-β1
effects. Further, a role of miR-10b in proliferation and
growth of CSCs, in vitro as well as in vivo, has also been re-
ported [34]. Thus, it appears that miR-10b is functionally
involved in the induction of EMT and CSCs phenotypes,
which would explain its role in drug resistance phenotype,
such as tamoxifen resistance as observed in our study.
While our work is the first report on mechanistic involve-
ment of miR-10b in drug resistance of breast cancer cells,
such role of miR-10b in other cancer models has been re-
ported. miR-10b was observed to be consistently high in all
the cisplatin resistant sublines derived from parental
cisplatin-sensitive germ cell tumor cell lines [35], and it was
reported to confer resistance to 5-fluorouracil in colorectal
cancer cells [36]. Clearly, there is evidence in support of
miR-10b-mediated induction of drug resistance which is in
direct agreement with our findings.
The miRNA-mediated regulation of tamoxifen resist-
ance has been studied in breast cancer models for many
years where miR-221 and miR-222 are the most well
characterized microRNAs [6, 5, 37, 38]. These oncogenic
miRNAs confer resistance to tamoxifen through down-
regulation of tumor suppressors p27Kip1 [6, 38] and
TIMP3 [37]. Another oncogenic miRNA, miR-519a in-
duces tamoxifen resistance via regulation of several
tumor suppressor genes in PI3K pathway [12]. Not all
miRNAs that are functionally involved in tamoxifen re-
sistance are oncogenic. Tumor suppressors miR-15a and
miR-16 regulate tamoxifen sensitivity by targeting Bcl-2
[7], miR-451 targets 14-3-3ζ [39], let7s target ER-α36
[15], miR-375 targets metadherin [9] and miR-200b/c
target ZEB1 [10]. Also, an elevated expression of miR-126
and miR-10a has been linked to better prognosis and lon-
ger relapse-free time in breast cancer patients treated with
tamoxifen [11]. Thus, the regulation of sensitivity to tam-
oxifen is influenced by both oncogenic and tumor suppres-
sive miRNAs. Our results are suggestive of an oncogenic
role of miR-10b. We used multiple bioinformatics-based
methodologies to find a functionally viable target of
miR-10b in our model system. Using IPA and online
tools, we identified HDAC4 as a target of miR-10b, which
was correlated with tamoxifen resistance/sensitivity, as de-
termined by over-expression/silencing studies.
HDAC4 is a member of class IIa histone deacetylases
and our results support an inverse relationship between
HDAC4 expression and tamoxifen resistance. This is
surprising, given the focus on HDAC inhibitors as anti-
cancer agents. Consistent with the many reports on
tumor-progressing role of HDACs, HDAC4 has been re-
ported to be tumorigenic in different human cancers
[40, 41]. Indicative of a tumor suppressor function of
HDAC4 is the observation that HDAC4 was down-
regulated in 15 of 18 urothelial cancer cell lines [42].
The paradox of HDAC4 activity also extends to its in-
volvement in drug resistance. A number of reports
present a positive correlation between HDAC4 expres-
sion and drug resistance. For instance, HDAC4 was
shown to activate STAT1 leading to platinum resistance
in ovarian cancer patients-derived cell lines [43] and re-
sistance to etoposide in lung cancer cells [44]. HDAC4
also induced resistance to 5-fluorouracil in breast cancer
cells [45] and inhibited docetaxel-related cytotoxicity in
gastric cancer cells [46]. A careful review of the litera-
ture revealed that the only miRNA that has been associ-
ated with HDAC4, in the context of drug resistance, is
miR-140 [47]. Interestingly, this study found a very simi-
lar function of HDAC4, as observed by us in the current
study. Performed in colon and osteosarcoma cells, this
study reported higher miR-140 expression in colon CSCs
with increased resistance to 5-fluorouracil. HDAC4 in-
hibition was proposed as the mechanism of miR-140-
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induced chemoresistance. Thus, the only published work
that investigated miRNA regulation of HDAC4 in resist-
ant cells documented similar findings consistent with
our results. In an earlier published work [48], we dem-
onstrated that inhibitors of HDACs, such as Trichostatin
A (TSA) and Suberoylanilide hydroxamic acid (SAHA),
induced EMT in prostate cancer cells, as evidenced by
up-regulated markers of mesenchymal phenotype. Fur-
ther, TSA treatment resulted in increased expression of
Sox2 and nonog indicating an enrichment of CSCs.
Thus, antagonizing HDACs made the cancer cells more
invasive, which is in agreement with our current find-
ings, and, moreover, we provide here a mechanism
through the novel involvement of miR-10b. It is tempt-
ing to suggest that such EMT/CSC-inducing activity of
HDAC inhibitors might be a factor for their disappoint-
ing progress in clinical trials. Combined with the results
from this study where low levels of HDAC4 correlated
with drug resistance, it is important that the mechanistic
involvement of HDACs in EMT, CSCs and drug resistance
be evaluated in-depth before their selective targeting in
clinics.
Conclusions
The preliminary evidences supporting functional role of
reduced HDAC4 in drug resistant cancer cells are avail-
able and more detailed studies need to be performed to
further understand the complex relationship between
microRNAs, HDACs, EMT and CSCs – all of which play
important roles in determining response to conventional
therapeutics. In recent years, the concept of personalized
medicine has gained a lot of attention. The epigenetic
approach for personalized medicine has largely focused
on methyltransferases and the histone deacetylases. To-
wards this end, further characterization of the function
of HDAC4 in drug resistance will be an important step
forward towards realizing the goal of personalized medi-
cine in the management of breast cancer patients, par-
ticularly those with recurrent disease.
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